Alkermes
plc ALKS today announced that data will be presented at
the 52nd Annual Meeting of the American College of
Neuropsychopharmacology (ACNP) in Hollywood, Fla., Dec. 8-12, 2013,
related to the company's two most advanced clinical candidates,
aripiprazole lauroxil, a long-acting injectable treatment for
schizophrenia, and ALKS 5461, a novel oral compound for the treatment of
major depressive disorder (MDD). Enrollment in the phase 3 study for
aripiprazole lauroxil has been completed, and ALKS 5461 is expected to
enter phase 3 clinical trials in 2014.
Details for these presentations at the ACNP meeting include:
Monday, Dec. 9, 2013, 5:30-7:30 p.m. EST
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in